Adheren Inc | Date: 2014-12-27
Active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancer and other diseases.
Adheren Inc | Date: 2014-09-26
Active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancer or diseases.
Hsiao C.-W.,Adheren Inc. |
Lo Y.-T.,Adheren Inc. |
Liu H.,Eureka Therapeutics |
Hsiao S.C.,Adheren Inc.
Journal of Visualized Experiments | Year: 2014
A live cell-based whole blood cytotoxicity assay (WCA) that allows access to temporal information of the overall cell cytotoxicity is developed with high-throughput cell positioning technology. The targeted tumor cell populations are first preprogrammed to immobilization into an array format, and labeled with green fluorescent cytosolic dyes. Following the cell array formation, antibody drugs are added in combination with human whole blood. Propidium iodide (PI) is then added to assess cell death. The cell array is analyzed with an automatic imaging system. While cytosolic dye labels the targeted tumor cell populations, PI labels the dead tumor cell populations. Thus, the percentage of target cancer cell killing can be quantified by calculating the number of surviving targeted cells to the number of dead targeted cells. With this method, researchers are able to access time-dependent and dose-dependent cell cytotoxicity information. Remarkably, no hazardous radiochemicals are used. The WCA presented here has been tested with lymphoma, leukemia, and solid tumor cell lines Therefore, WCA allows researchers to assess drug efficacy in a highly relevant ex vivo condition. © 2014, Journal of Visualized Experiments. All rights reserved. Source
Adheren Incorporated and Adheren Inc | Date: 2014-09-26
Active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancer and diseases.
Hsiao S.C.,Adheren Inc. |
Liu H.,Eureka Therapeutics |
Holstlaw T.A.,Adheren Inc. |
Liu C.,Eureka Therapeutics |
And 3 more authors.
PLoS ONE | Year: 2013
A new live cell-based assay platform has been developed for the determination of complement dependent cytotoxicity (CDC), antibody dependent cellular cytotoxicity (ADCC), and overall cytotoxicity in human whole blood. In these assays, the targeted tumor cell populations are first labeled with fluorescent Cell Tracker dyes and immobilized using a DNA-based adhesion technique. This allows the facile generation of live cell arrays that are arranged arbitrarily or in ordered rectilinear patterns. Following the addition of antibodies in combination with serum, PBMCs, or whole blood, cell death within the targeted population can be assessed by the addition of propidium iodide (PI) as a viability probe. The array is then analyzed with an automated microscopic imager. The extent of cytotoxicity can be quantified accurately by comparing the number of surviving target cells to the number of dead cells labeled with both Cell Tracker and PI. Excellent batch-to-batch reproducibility has been achieved using this method. In addition to allowing cytotoxicity analysis to be conducted in real time on a single cell basis, this new assay overcomes the need for hazardous radiochemicals. Fluorescently-labeled antibodies can be used to identify individual cells that bear the targeted receptors, but yet resist the CDC and ADCC mechanisms. This new approach also allows the use of whole blood in cytotoxicity assays, providing an assessment of antibody efficacy in a highly relevant biological mixture. Given the rapid development of new antibody-based therapeutic agents, this convenient assay platform is well-poised to streamline the drug discovery process significantly. © 2013 Hsiao et al. Source